Locations:
Search IconSearch
December 9, 2025/Cancer/News & Insight

Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

church bus tour

Black Americans have a significantly higher incidence, severity and mortality from venous thromboembolism (VTE) compared to other racial and ethnic groups. Despite this elevated risk, awareness and education about VTE remain limited in many Black communities.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

To address this knowledge gap, the National Blood Clot Alliance launched the Black Lives Advocating for Clot Knowledge (B.L.A.C.K) Church Bus Tour, which partnered with faith-based institutions in southeastern Black communities. This program aimed to empower individuals to recognize VTE risk factors and symptoms, know when to seek prompt care and learn about preventive actions.

A bold approach

Featuring a bright-red bus with signage describing VTE symptoms, the campaign educated individuals to take steps to reduce the risk of VTE and to recognize the condition when it occurs. The bus tour included four churches in Charlotte, NC, Marietta, GA and Memphis, TN. The tour incorporated educational sessions and the distribution of educational materials.

Researchers collected pre- and post-event surveys to assess changes in knowledge resulting from the program. The findings were presented at the 2025 ASH annual meeting.

“The NBCA bus tour campaign underscores the value of culturally tailored educational interventions in addressing gaps in VTE awareness,” says Dana Angelini, MD, a physician in the Classical Hematology team at Cleveland Clinic Cancer Institute.

Program demographics

More than 450 people participated in the events across the southeastern U.S. The majority of participants were between 61-70 years old, and 73.1% were female. Most participants identified as Black, non-Hispanic.

Roughly 89% participants said they had not personally experienced a blood clot and they did not have a friend or family member who had experienced one.

Advertisement

Increasing awareness

Wilcoxon signed-rank test was used to compare section and total survey scores before and after the program. Analysis of the pre- and post-surveys found a statistically significant increase in awareness across 16 knowledge domains. In addition to gaining knowledge about symptoms and treatments, the overwhelming majority of participants also strongly agreed to make lifestyle changes to reduce their risk of contracting VTE.

Additionally, most participants reported their intention to share this knowledge in the community. “This finding demonstrates the power that community education has to spread awareness to those who are in front of us and beyond,” says Dr. Angelini.

What’s next

Based on the success of the program, the National Blood Clot Alliance is working on a “2.0” version of the bus tour, and hopes to make this an annual endeavor. The plan is to continue to raise awareness in the hopes of fostering earlier intervention and risk mitigation and ultimately reduce VTE-associated mortality rates. “This initiative highlights the importance of meeting people where they are, in environments where they feel comfortable, and providing them with trusted health education.,” says Dr. Angelini.

Advertisement

Related Articles

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Lobular breast cancer cells
December 22, 2025/Cancer/Innovations
Comprehensive Lobular Breast Cancer Program Addresses Often-Misunderstood Disease

Care paths and research initiatives aim to answer unmet clinical needs

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

Dr. Gerds
December 8, 2025/Cancer/News & Insight
AI Screening Platform Accelerates Trial Recruitment in Polycythemia Vera

AI-driven tools can streamline enrollment and improve efficiency across clinical trials.

Ad